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ABSTRACT
Clostridium difficile should be suspected in patients who present with nosocomial diarrhoea. It is more
common in the elderly or in patients with a debilitating underlying condition who have received
antimicrobial agents, and up to 20–25% of patients may experience a relapse. The reference method for
diagnosis is the cell culture cytotoxin test which detects the presence of toxin B in a cellular culture of
human fibroblasts, but recovering C. difficile in culture allows the performance of a ‘‘second-look’’ cell
culture assay that enhances the potential for diagnosis. Oral metronidazole (500 mg tid or 250 mg every
6 hrs) and oral vancomycin (125 mg every 6 hrs) administered for 10–14 days have similar therapeutic
efficacy, with response rates near 90–97%. C. difficile strains resistant to metronidazole and with
intermediate resistance to vancomycin have been described. The administration of probiotics such as
Saccharomyces boulardii, Lactobacillus sp. or brewer’s yeast for prophylaxis of CDAD remains controversial.
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INTRODUCTION
Clostridium difficile is a Gram-positive sporulated
rod that grows in anaerobic conditions after
24–48 h [1] (Fig. 1). It is a ubiquitous microorgan-
ism that colonises up to 3–5% of adult humans. It
proliferates in the colon of patients treated with
antimicrobial agents, and certain strains can
produce two toxins: toxin A, which is mainly
responsible for diarrhoea (enterotoxin), and toxin
B, a cytotoxin used in diagnosis.
C. difficile is the main cause of nosocomial
diarrhoea with identified aetiology. It is respon-
sible for considerable patient morbidity and cost
to the healthcare system [2,3]. A conservative
estimate of the cost of this disease in the USA is
more than $1.1 billion per year [4].
First described in 1935 [5], the role of C. difficile
in antibiotic-related diarrhoea was not recognised
until the 1970s [6–8]. The incidence ranges from 2
to 30 cases per 1000 hospital admissions [9–14].
EPIDEMIOLOGY AND RISK FACTORS
C. difficile is demonstrated in approximately 20%
of antimicrobial-related diarrhoea. The aetiology
of the remaining 80% is still unknown, although
the potential implication of other microorgan-
isms, such as Clostridium perfringens, Staphylococ-
cus aureus or Candida albicans, has been
proposed.
Most cases of C. difficile-associated diarrhoea
(CDAD) are acquired in hospitals, although com-
munity-acquired cases are increasingly being
reported [15,16].
The most important risk factor for CDAD is the
use of an antimicrobial agent during the previous
1–8 weeks (90% of cases), even in the form of a
single prophylactic dose.Almost any antimicrobial
agent may cause CDAD, although the risk is
claimed to be especially high after the administra-
tion of clindamycin [17]. Other implicated drugs
include ampicillin, amoxicillin and cephalospo-
rins, amongst others [18], including even vanco-
mycin and metronidazole [19,20] (Table 1).
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Other risk factors for the development of
CDAD include advanced age, previous surgery
and immunodepression, including transplanta-
tion and human immunodeficiency virus infec-
tion [21–28].
CLINICAL MANIFESTATIONS
CDAD should be suspected in patients who
present with nosocomial diarrhoea. As mentioned
above, it is more common in the elderly and in
patients with a debilitating underlying condition
who have received antimicrobial agents [14,29].
The definition of CDAD includes the presence
of diarrhoea (at least five bowel movements with
liquid or unformed stools during the last 36 h),
the use of antimicrobial agents within the previ-
ous 8 weeks, the detection of C. difficile toxin, a
therapeutic response to specific therapy and the
exclusion of other entities. Pseudomembranes in
the colon are present in less than 25% of the most
severe episodes (pseudomembranous colitis)
(Fig. 2).
The clinical manifestations of CDAD range
from mild diarrhoea to a life-threatening disease,
such as pseudomembranous colitis or toxic mega-
colon [30]. The severity of the disease may depend
on the host characteristics and on the virulence
and inocula of the pathogen. Patients with CDAD
usually present with malaise, abdominal cramps
or pain, nausea, vomiting, liquid diarrhoea, fever
and leucocytosis, which may be very severe
[31–33]. C. difficile should be considered as one of
the main causes of a high white cell count of
unknown origin amongst hospitalised patients
[31]. The endoscopic examination of the colon
usually reveals diffuse or scattered erythema [34].
Other findings may include hypoalbuminaemia
and the presence of leucocytes in the stools [35].
Pseudomembranous colitis occurs in less than
25% of patients with CDAD and is characterised
by the presence of white-yellowish plaques
(2–10 mm) in any segment of the colon [34]. The
detection of pseudomembranes is a poorly sensi-
tive but highly specific sign and is almost path-
ognomonic of the disease [14,36]. In up to 20% of
patients, the lesions are only present in the
proximal colon and are thus difficult to demon-
strate. The involvement of the small bowel is rare,
although possible [30].
A small, although increasing, proportion of
patients present with fulminant colitis. In a recent
study, the incidence of patients with life-threat-
ening C. difficile colitis evolved from 1.6% to 3.2%.
Forty-four patients required a colectomy and 20
others died because of C. difficile colitis. Common
predisposing conditions for these severe presen-
tations are a recent surgical procedure and im-
munosuppression. Lung transplant patients were
46 times more likely to have C. difficile colitis and
eight times more likely to have severe disease in
this series. Abdominal computed tomography
scan correctly diagnosed all patients, whereas
12.5% of toxin assays and 10% of endoscopies
were falsely negative. Patients undergoing colec-
tomy for C. difficile colitis had an overall death
rate of 57%. Significant predictors of death after
colectomy were pre-operative vasopressor
requirements and age [37]. These patients usually
show intense abdominal pain, severe diarrhoea,
fever and marked leucocytosis. In some cases,
there is no diarrhoea, which is claimed to be a
poor prognostic factor of the presence of toxic
megacolon. These patients may have hypoalbu-
minaemia and even ascites. Perforation, perito-
nitis and even death have been described. The
performance of colonoscopy under these circum-
stances is contraindicated because of the risk of
perforation [30,34]. Sometimes the diagnosis is
only established after death [38,39].
Up to 20–25% of patients may experience a
relapse [40–42], which may be very difficult to
manage, as discussed later in this article. The
reasons for these relapses are not clear-cut, but
some authors have suggested that a serum anti-
body response to toxin A, during an initial
episode of C. difficile diarrhoea, is associated with
protection against recurrence [43].
The main differential diagnosis of CDAD is
antimicrobial-related diarrhoea. This entity may
appear in patients of any age, is related to the type
and dose of antimicrobial agent used, has less
severe clinical manifestations and is rarely asso-
ciated with leucocytosis or toxic megacolon. In
antimicrobial-related diarrhoea, the detection of
the toxin is negative and the withdrawal of anti-
microbial therapy is sufficient treatment. Some
data suggesting a diagnosis of CDAD include an
onset of diarrhoea > 6 days after the administra-
tion of antimicrobial agents (odds ratio (OR),
1.38), a hospital stay longer than 15 days (OR,
1.33), the presence of leucocytes in the faeces
(OR, 2.3) and the previous use of cephalosporins
(OR, 2.3) [35].
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Extra-intestinal infection is very uncommon
(four cases per 100 000 admissions) [44]. In most
cases, the sample was obtained from the abdom-
inal cavity, raising the possibility of intestinal
contamination and spillage (peritoneal fluid,
intra-abdominal abscesses or wounds). However,
C. difficile was recovered in five patients in our
service from samples not in the anatomic vicinity
of the colon (one brain abscess, two episodes of
bacteraemia and two foot infections) [44]. In all
but one case, C. difficile isolation was obtained as
part of a polymicrobial flora. The isolates were
frequently non-toxigenic and the extra-intestinal
infections occurred without concomitant diar-
rhoea or previous antimicrobial therapy.
Fig. 1. Gram stain of Clostridium difficile showing charac-
teristic Gram-positive rods.
Fig. 2. Endoscopic aspect of pseudomembranes in a
patient with Clostridium difficile-associated diarrhoea.
(Courtesy of the Department of Digestive Medicine of the
Hospital Gregorio Maran˜o´n, Madrid, Spain.)
Fig. 3. Clostridium difficile colonies on cycloserine cefoxitin
fructose agar.
Table 1. Antimicrobial agents related to Clostridium diffi-
cile-associated diarrhoea
Very frequently Frequently Infrequently








Table 2. Characteristics of the main diagnostic techniques for Clostridium difficile-associated diarrhoea
Method Detects Pros Cons









Toxin B High sensitivity Sophisticated equipment
Requires 72–92 h
Enzyme immunoassay test Toxin A or A + B Specific and rapid Low sensitivity
Polymerase chain reaction Different targets High sensitivity and specificity Costly and time-consuming technique
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DIAGNOSIS
The Infectious Disease Society of America [45]
and the Society for Healthcare Epidemiology of
America [46] have recently published recommen-
dations concerning the diagnosis of CDAD [39].
Although the review of all available diagnostic
methods of CDAD is beyond the scope of this
article, we briefly mention the pros and cons of
the most common diagnostic methods (Table 2).
The diagnosis is usually based on the analysis
of fresh diarrhoeic stools. The sample should be
promptly sent to the laboratory. Well-formed
stools and samples from patients younger than
1 year of age should be rejected in the laboratory.
Rapid staining techniques, such asGram stain or
fluorescent antibodies, are not recommended [47].
The standard method is the cell culture cyto-
toxin test, which detects the presence of toxin B in
a cellular culture of human fibroblasts (MRC5)
[48,49]. This method takes 48–72 h and has a
sensitivity of 67–100% and a specificity of 85–
100%. The false negative results may be related to
the destruction of pre-formed toxin or to the
presence of a quantity of toxin which is too low to
induce the cytopathic effect.
In our laboratory, the stool samples submitted
for direct cell culture are also plated onto cyclo-
serine cefoxitin fructose agar (Fig. 3). The per-
formance of culture permits the investigation of
the antimicrobial susceptibility and of outbreaks
by molecular methods. Cycloserine cefoxitin fruc-
tose agar [50] is highly selective for C. difficile. The
morphology of the colony will depend on the
culture medium used [38]. The recovery of
C. difficile in culture allows the performance of
what we call the ‘second-look’ cell culture assay.
C. difficile strains isolated from samples with a
negative direct cell culture assay are re-tested for
toxin production (‘second-look’ cell culture as-
say). We have tested both methods, and 15% of
our samples with positive assays were positive
only after the ‘second-look’ cell culture assay. The
combination of a direct cell culture assay, culture
for toxigenic C. difficile, and ‘second-look’ cell
culture assay enhances the potential for the
definitive diagnosis of CDAD, and allows for
more efficient use of patient care resources [51].
An alternative for laboratories that do not
have cellular culture facilities, or those that want
to provide rapid information to the clinician, is
the enzyme immunoassay test [52–54]. These
systems have a good specificity, but their sen-
sitivity is low, as they cannot detect quantities of
toxin below 100–1000 pg (the cellular culture
detects 10 pg). The rate of false negative results
usually exceeds 10–20%. Enzyme immunoassay
tests detect toxin A or both toxin A and B. The
latter are the most interesting, because recently
there have been reports of strains that produce
toxin B, but not toxin A [55].
Molecular techniques, such as polymerase chain
reaction, have also been successfully employed in
the diagnosis of CDAD, although their complexity
and cost prevent them from being adopted in the
laboratory on a routine basis [56–59].
With the exception of epidemiological studies
there is no need to perform any microbiological
test to confirm that the patient has been cured
once the symptoms have subsided.
TREATMENT
Healthy carriers should not receive therapy [34].
The first-line drugs for the therapy of CDAD are
metronidazole (oral or intravenous) and vanco-
mycin (only oral or rectal). The indications for
therapy are the detection of a toxin-producing
C. difficile strain in a patient with disease (diar-
rhoea, fever, leucocytosis and, occasionally, com-
patible findings on colonoscopy).
The first step of therapy is to reduce the
predisposing conditions, i.e., to withdraw anti-
microbial therapy if possible. Many patients will
also require supportive therapy with fluids. Anti-
peristaltic agents should be avoided and effective
antimicrobial therapy should be initiated
promptly.
Oral metronidazole (500 mg thrice daily or
250 mg every 6 h) and oral vancomycin (125 mg
every 6 h) have similar efficacy, with response
rates near 90–97% [60,61]. The normal duration of
therapy is 10–14 days, although there are no well-
performed studies that have established the poss-
ible advantage of shortening or lengthening this
course. Some authors recommend longer therapy
to avoid recurrence, but this premise has not been
proven. As mentioned previously, if the intraven-
ous route is required, only metronidazole is
effective, as intravenous vancomycin only
achieves low concentrations in the colon lumen
[36]. The therapeutic response usually involves
the resolution of fever on the first day and of
diarrhoea on the fourth or fifth day [36]. Metroni-
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dazole is preferred to vancomycin because of its
lower cost and because it does not increase the
appearance of vancomycin-resistant enterococci.
The indications for oral vancomycin are preg-
nancy, breast-feeding, metronidazole intolerance
or therapeutic failure of metronidazole after
3–5 days of treatment.
Most C. difficile infections respond to either
drug and therapeutic failure requires the confir-
mation of the diagnosis and the exclusion of ileitis
or toxic megacolon, as both conditions may
prevent the drugs from reaching sufficiently high
levels in the colon lumen. Patients with ileitis may
benefit from higher doses of oral vancomycin
(500 mg every 6 h) or from the local administra-
tion of vancomycin by means of enemas. Severely
ill patients who do not respond to conventional
therapy may require, in exceptional circum-
stances, the performance of a colostomy.
The most common complication of the treat-
ment of CDAD is relapse, which may occur in up
to 20–25% of cases [40,62]. Immunosuppressed
patients (transplant recipients and human immu-
nodeficiency virus-infected patients) have a high-
er index of relapse. Relapse should be suspected
when the symptoms reappear after a mean of
6 days (3–21 days) from completion of therapy. It
is important to remember that the detection of the
toxin may remain positive in one-third of patients
who have responded to therapy. Most relapses
respond to another 10-day course of therapy
with the same antimicrobial agent. However,
3–5% of patients may have subsequent relapses
[63]. In these cases, a longer duration of therapy
(4–6 weeks) has been proposed. Other alterna-
tives include the use of pulses of vancomycin
(125 mg ⁄day), the administration of resins to
absorb the toxins (4 g of colestyramine thrice
daily), the use of probiotics (Saccharomyces bou-
lardii or Lactobacillus) or the administration of
intravenous immunoglobulins [43,62,64]. It has
been demonstrated that 40% of the clinical recur-
rences are actually re-infections by a different
strain when molecular methods are used [41].
Patients with untreatable relapses should be
considered for treatment with immunoglobulins
as they usually have very low levels of antibodies
against C. difficile [65,66].
C. difficile strains resistant to metronidazole and
with intermediate resistance to vancomycin have




C. difficile is widely recovered from the environ-
ment of patients with CDAD, as well as from the
hands of healthcare workers [29,68]. Patients
acquire it from the environment or by faecal–oral
transmission via colonised or ill patients [69]. The
incubation period is unknown.
The prevention and control of CDAD include
the following steps: (i) the judicious use of
antibiotics; (ii) contact precautions; and (iii)
adequate environmental cleaning.
The restriction of antimicrobial usage is a
measure of proven efficacy in decreasing the
incidence of CDAD [46]. Some suggestions from
the Department of Health and Public Health
Laboratory Service Joint Working Party (1994) to
improve the control of CDAD include: (i) written
guidelines on correct antimicrobial use; (ii) restric-
tion of susceptibility reports by the microbiology
laboratory; (iii) programmes of continuous educa-
tion for healthcare workers (as well as patients and
their families); (iv) control and restriction of
antimicrobial agent prescriptions; (v) automatic
dates for termination of therapy; (vi) contact with
the microbiologist or infectious disease specialist
in special situations; (vii) avoidance of unneces-
sary use of antimicrobial agents; (viii) avoidance of
wide-spectrum antimicrobial agents when feas-
ible; (ix) avoidance of the use of antimicrobial
agents especially linked to a high-risk of CDAD;
(x) strict control of surgical prophylaxis [70].
No special isolation precautions are required,
but standard body substance precautions are
essential to avoid nosocomial transmission. The
CDC recommends contact precautions only for
symptomatic patients, except in special situations.
They include placement in a private room and, if
none is available, cohorting of these patients.
Healthcare workers should wear gloves when
entering a patient’s room [71], and gowns if
soiling of clothing is likely. Frequent hand-wash-
ing is highly recommended and it should be
remembered that C. difficile spores are resistant to
alcohol solutions used for hand hygiene. Finally,
dedicated equipment should be used whenever
possible. Precautions should continue until diar-
rhoea ceases.
Factors to be considered when deciding which
patients should be placed in isolation include the
severity of diarrhoea, the ability of the patient to
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take care of himself ⁄herself, the proximity of
elderly patients, the proximity of patients on
antimicrobial therapy, etc. [72].
The third step for the prevention of CDAD is
adequate environmental cleaning. As mentioned
above, C. difficile spores are highly resistant to the
action of disinfectants [73]. They can be recovered
from almost every surface in the room of patients
with CDAD [74], as well as from thermometers
[75] or stethoscopes [76].
The CDC recommends adequate cleaning and
disinfection of the environment and medical
devices, especially items likely to be contaminated
by faeces, and that manufacturer’s instructions for
endoscopic and other device disinfection should
be followed. The Environmental Protection
Agency-approved hospital disinfectants should
be used for environmental cleaning [20].
The administration of probiotics for the pro-
phylaxis of CDAD, such as S. boulardii [77],
Lactobacillus sp. [64,78], yogurt [79] or brewer’s
yeast [80], remains controversial. There have also
been reports of passive immunisation [81] and
vaccines [82].
CONCLUSION
Clostridium difficile is an ubiquous microorganism
that colonises up to 3–5% of adult human beings.
It proliferates in the colon of patients who have
been treated with antimicrobial agents, and some
of the strains are able to produce two toxins: toxin
A, mainly responsible for diarrhoea (enterotoxin),
and toxin B, a cytotoxin which is used in the
diagnosis. Most cases of C. difficile-associated
diarrhoea (CDAD) are acquired in the hospital,
although community-acquired cases are increas-
ingly reported. Patients with CDAD usually
present with malaise, abdominal cramps or pain,
nausea, vomiting, liquid diarrhoea, fever and
leukocytosis. C. difficile should be considered
one of the main causes of a high white cell count
of unknown origin among hospitalised patients.
A small, though rising, proportion of patients
present with fulminant colitis and extraintestinal
infection is very uncommon.
A diagnostic alternative for the laboratories
which do not have cellular culture facilities are
the enzyme immunoassay tests. These systems
have a good specificity, but their sensibility is low.
The first step of treatment is to withdraw the
antimicrobial therapy if possible. Metronidazole
is the drug of first choice and vancomycin should
be reserved for cases involving pregnancy, breast-
feeding, metronidazole intolerance, or therapeutic
failure with metronidazole. Patients with untrea-
table relapses must be considered for treatment
with immunoglobulins as they usually have very
low levels of antibodies against C. difficile. The
prevention and control of CDAD includes judi-
cious use of antibiotics, contact precautions and
adequate environmental cleaning.
Since this manuscript was accepted for pub-
lication, Pe´pin et al [83] from Canada and Musher
et al [84] from the USA reported on the increasing
risk of poor outcomes or relapses in patients
receiving metronidazole treatment in recent years
in their respective areas of practice. This is
certainly an area for concern and future research.
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